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ABSTRACT 
 
Rationale: Transplantation-accelerated arteriosclerosis is one of the major challenges for long-term 
survival of patients with solid organ transplantation. Although stem/progenitor cells (SPCs) have been 
implicated to participate in this process, the cells of origin and underlying mechanisms have not been fully 
defined.  
 
Objective: The objective of our study was to investigate the role of c-Kit lineage cells in allograft-induced 
neointima formation, and to explore the mechanisms underlying this process.  
 
Method and Results: Using an inducible lineage tracing Kit-CreER;Rosa26-tdTomato mouse model, we 
observed that c-Kit is expressed in multiple cell types in the blood vessels, rather than a specific SPC marker. 
We performed allograft transplantation between different donor and recipient mice, as well as bone marrow 
transplantation experiments, demonstrating that recipient c-Kit+ cells repopulate neointimal smooth muscle 
cells (SMCs) and leucocytes, and contribute to neointima formation in an allograft transplantation model. 
c-Kit-derived SMCs originate from non-bone marrow tissues, while bone marrow-derived c-Kit+ cells 
mainly generate CD45+ leucocytes. However, the exact identity of c-Kit lineage cells contributing to 
neointimal SMCs remains unclear. ACK2, which specifically binds and blocks c-Kit function, ameliorates 
allograft-induced arteriosclerosis. Stem cell factor (SCF) and transforming growth factor β1 (TGF-β1) 
levels were significantly increased in blood and neointimal lesions after allograft transplantation, by which 
SCF facilitated c-Kit+ cell migration through the SCF/c-Kit axis and downstream activation of small 
GTPases, MEK/ERK/MLC and JNK/c-Jun signaling pathways, while TGF-β1 induces c-Kit+ cell 
differentiation into SMCs via hexokinase1-dependent metabolic reprogramming and a possible downstream 
O-GlcNAcylation of myocardin and serum response factor.  
 
Conclusions: Our findings provide evidence that recipient c-Kit lineage cells contribute to vascular 
remodeling in an allograft transplantation model, in which the SCF/c-Kit axis is responsible for cell 
migration and hexokinase1-dependent metabolic reprogramming for SMC differentiation. 
 
Keywords: Stem cells, transplantation, arteriosclerosis, lineage tracing, metabolism. 
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Non-standard Abbreviations and Acronyms 
2-DG 2-Deoxyglucose 
Acta2/α-SMA α-Smooth muscle actin 
Cdc42 Cell division cycle 42 
Cnn1 Calponin 1 
DON 6-Diazo-5-oxo-L-norleucine 
ECAR Extracellular acidification rate 
ECs Endothelial cells 
FAK Focal adhesion kinase 
HK Hexokinase 
MLC Myosin light chain 
Myh11 Smooth muscle myosin heavy chain 11 
OCR Oxygen consumption rate 
PDGFRα Platelet-derived growth factor receptor α 
PYG Glycogen phosphorylase 
Rac1 Rac family small GTPase 1 
tdTomato/tdT Tandem dimer Tomato 
RhoA Ras homolog family member A 
Sca-1/Ly6a Stem cell antigen-1/lymphocyte antigen 6 complex, locus A 
SCF Stem cell factor 
SM22/Tagln Smooth muscle protein 22/Transgelin 
SMCs Smooth muscle cells 
SPCs Stem/progenitor cells 
SRC Spare respiratory capacity 
UDP-GlcNAc Uridine diphosphate-N-acetylglucosamine 
 
 
INTRODUCTION  
 
Establishment of organ transplantation gives hope for patients suffering from end-stage of organ 
failure1. While graft failure and multiple organ dysfunctions are leading causes of death in the early years 
after transplantation, transplant arteriosclerosis is highly related to poor prognosis and severely limits the 
long-term survival of patients. Transplantation-accelerated arteriosclerosis is initiated by acute innate and 
acquired immune responses2, which lead to endothelial cell (EC) damage and dysfunction, followed by 
smooth muscle cell (SMC) accumulation to form the lesions1. The critical role of SMCs in arteriosclerosis 
has been extensively established3, but the origin of neointimal SMCs remains controversial4. It was 
historically believed that medial SMCs undergo phenotypic switching, migrate to the intimal region and 
proliferate to form neointima5. However, neointimal SMCs have been found to be heterogeneous, and recent 
studies have revealed various origins of SMCs may contribute to neointima formation6, 7. In addition to 
medial SMCs, various cell types including ECs which may undergo endothelial-to-mesenchymal transition, 
bone marrow-derived or circulating SMC progenitors, fibroblasts as well as vascular resident 
stem/progenitor cells (SPCs), have been reported to be possible regulators in this process8-14.  
 
 Genetic lineage tracing has proved to be a powerful tool to track stem cell fate and identify the progeny 
of specific cell types during embryonic development as well as in disease models15. Based on inducible 
lineage tracing models, Kramann et al.13 have shown that adventitia Gli1+ mesenchymal stem cell-like cells 
are important sources of neointimal SMCs in injured arteries, while Roostalu et al.16 revealed that CD146+ 
immature SMC progenitors in arterial branch sites also contribute to neointima formation in a similar wire-
injury model, in which they further proposed that neointimal SMCs may arise from adventitial SPCs. Our 
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group previously identified SPCs expressing stem cell antigen-1 (Sca-1), c-Kit and/or CD34 in aortic 
adventitia12. When expanded in cell culture and seeded on adventitia of a vein graft model, these SPCs 
differentiated into SMCs and contributed to neointima formation12, suggesting a potential role of these SPCs 
in vessel remodeling. However, the precise contribution of SPCs to SMC accumulation in transplant 
arteriosclerotic lesions remains unknown. 
 
 In this study, we used Kit-CreER;Rosa26-tdTomato mice, an inducible lineage tracing model, to trace 
the fate of c-Kit lineage cells in an aortic allograft mouse model. Our results surprisingly showed that c-Kit 
labels multiple cell types in the aortic wall. c-Kit+ cells repopulate neointimal SMCs and contribute to 
neointimal formation in aortic grafts. The origin of these c-Kit-derived SMCs are from recipient non-bone 
marrow tissues, whereas bone marrow c-Kit+ cells mainly generate leucocytes. Additionally, we confirmed 
the SMC differentiation potential of isolated c-Kit+ cell in vitro. We further investigated possible underlying 
mechanisms for SMC differentiation from c-Kit+ cell, and revealed that stem cell factor (SCF) triggers cell 
migration through SCF/c-Kit signaling pathway, while TGFβ1 induces SMC differentiation via metabolic 
reprogramming.  
 
 
METHODS 
 
The data that support the findings of this study are available on reasonable request. All animal experiments 
performed were approved by the UK Home Office (PPL70/8944). 
 
An additional Detailed Methods section is provided in the Online Data Supplements.  
 
 
RESULTS 
 
Characterization of c-Kit+ cells in the aorta. 
 
To characterize and establish the distribution of vascular resident c-Kit+ cells, we stained aorta isolated 
from wildtype C57BL/6J mice for c-Kit, together with Sca-1, CD34, platelet-derived growth factor receptor 
α (PDGFRα) and CD45. As expected, c-Kit+ cells were mainly located in the adventitia (Figure 1A). A 
majority of c-Kit+ cells expressed classical SPC markers Sca-1 (~60%) and CD34 (~44%). Only ~9% of c-
Kit+ cells co-expressed PDGFRα, a marker for fibroblast or mesenchymal stem cell. Interestingly, we also 
identified a large population (~41%) of c-Kit+ CD45+ cells (Figure 1A and 1E), which could be leucocytes. 
However, considering that most mature immune cells do not express c-Kit17, this population may also be a 
subpopulation of recently identified adventitial macrophage progenitor cells distinct from circulating 
leucocytes18, 19. Additional en face staining further confirmed distribution of c-Kit+ cells co-expressing Sca-
1 and CD34 in the aortic adventitia (Online Figure IA). To further address the characterization of c-Kit+ 
cells, a Kit-CreER;Rosa26-tdTomato mouse was employed20, 21. Tandem dimer tomato (tdTomato) 
specifically labels c-Kit+ cells upon tamoxifen injection. Kit-CreER;Rosa26-tdTomato mice were pulsed 
with tamoxifen and analyzed for tdTomato expression one week later (Figure 1B). Flow cytometric analysis 
showed successful labeling of tdTomato in bone marrow, aorta and other established c-Kit expressing 
tissues (Figure 1C, Online Figure II). We also observed cells co-expressing both tdTomato and c-Kit in the 
aortic adventitia (Figure 1D). Consistent with our results from wildtype mice, a similar proportion of 
tdTomato+ cells expressing Sca-1 (~71%), CD34 (~47%), PDGFRα (~18%) and CD45 (~46%) were 
observed (Figure 1D-1E, Online Figure III). Specifically, ~30% of the tdTomato+ cells were Sca-1+ CD34+ 
(Online Figure III). tdTomato was rarely detected in the media, however, we did observe a minor population 
of medial SMCs labeled by tdTomato, representing ~0.1% of total medial SMCs (Online Figure IV). These 
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data collectively indicate that, although c-Kit was previously thought to be a specific SPC marker and did 
label a population of previously identified SPCs in the aorta, vascular c-Kit+ cells actually turn out to be a 
heterogeneous population. Besides, a c-Kit+ population expressing Sca-1 and/or CD34, a possible 
subpopulation of hematopoietic stem cells, was also observed in the bone marrow (Online Figure IB).  
 
Recipient c-Kit+ cells repopulate SMCs in the neointima of allograft model. 
 
We further tested whether c-Kit+ cells may contribute to neointima formation during vascular 
remodeling. We used a transplant arteriosclerosis mouse model as previously described22, in which donor 
aortic segments from BALB/c mice were transplanted into recipient C57BL/6J mice (Online Figure VA). 
We23 and others24-26 have previously demonstrated that transplant arteriosclerosis is a severe vascular injury 
model caused by alloimmune reaction, which may possibly induce cell apoptosis in all vascular layers (ECs, 
SMCs or even adventitial cells). Immunostaining showed neointima formation after allograft 
transplantation (Online Figure VB). Importantly, c-Kit+ cells expressing Sca-1 and CD34 were found in the 
neointima, with a significantly higher number compared to normal aorta (Online Figure VC), suggesting a 
possible role of c-Kit+ SPCs in allograft-induced neointima formation.  
 
 Genetic lineage tracing of c-Kit+ cells was next performed using Kit-CreER;Rosa26-tdTomato mice. 
Mice pulsed with tamoxifen were subjected to an allograft transplantation surgery, in which aorta segments 
from BALB/c mice were transplanted into Kit-CreER;Rosa26-tdTomato mice. Grafts with adjacent carotid 
arteries were collected four weeks later for analyses (Figure 2A). Whole mount fluorescence images showed 
that aortic graft (from donor wildtype BALB/c mice) was strongly labeled by tdTomato, with a relatively 
even distribution across the whole graft (Figure 2B). Immunostaining confirmed the abundant accumulation 
of tdTomato+ cells in the neointimal lesions (Online Figure VI), indicating that c-Kit+ cells may participate 
in allograft-induced neointima formation. As SMCs are the major component of the neointima, we further 
explored whether c-Kit+ cells give rise to neointimal SMCs. Grafts with adjacent tissues were divided into 
different zones for analyses (Figure 2C). Carotid artery from zone 1, which lies distal from the site of 
anastomosis, showed normal and similar morphology as healthy artery, with SM22+ SMCs detected in the 
media and tdTomato+ cells in the adventitia (Figure 2D). In zone 2, where carotid artery is proximal to the 
site of anastomosis and encompasses the suture site (consisting of carotid artery, cuff and graft), a large 
number of tdTomato+ cells were detected in the carotid artery, a connecting region between the carotid 
artery and a region outside the cuff (Figure 2D). This region outside the cuff could be some parts of carotid 
artery and/or allograft. A small population of SM22+tdTomato+ cells were also observed in both medial and 
adventitial layers (Figure 2D-2E). Of note, the labeling of SMC by c-Kit is variable in different regions of 
the adjacent carotid artery, with a much higher percentage (~12.9%) of medial tdTomato+ SMC in zone 2, 
compared to a lower percentage (~0.1%) in carotid artery distant to the graft (zone 1). Zone 3 and zone 4 
are aortic grafts proximal to, or distal from the site of anastomosis, respectively (Figure 2C). While zone 3 
formed a more severe and irregular neointima, zone 4 formed a more organized neointima (Figure 2D). 
SM22+tdTomato+ cells were detected in both zones, with 30.9 ± 4.4% of neointimal SM22+ SMCs in zone 
3, and 10.6 ± 1.2% in zone 4 labeled by tdTomato (Figure 2D-2E). Notably, the labeling of total neointimal 
SMCs by tdTomato is highly variable even in the same zone of the aortic grafts, ranging from 6.2% to 55.4% 
in zone 3, and from 5.2% to 18.0% in zone 4 (Figure 2D-2E, Online Figure VII). These data suggest that c-
Kit+ cells repopulate neointimal SMCs. Furthermore, the higher proportion of c-Kit-derived neointimal 
SMCs in zone 3 than zone 4, and the seemingly expansion of c-Kit+ cells in carotid artery (zone 2), suggest 
a possibility that a specific population of c-Kit+ cells may migrate from adjacent carotid artery to the graft 
and generate neointimal SMCs. Interestingly, a population of SM22+tdTomato+ cells were also observed in 
the adventitia of the aortic graft, with a similar proportion in both zone 3 and 4 (Figure 2D-2E, Online 
Figure VII). Single cell suspensions were also obtained from aortic grafts and analyzed by immunostaining 
and flow cytometry, further confirming the existence of c-Kit-derived SMCs (Online Figure VIII). 
Collectively, these data suggest c-Kit+ cells give rise to neointimal SMCs. As tdTomato only labeled 
recipient cells in this model, our results also indicate that recipient c-Kit+ cells repopulate neointimal SMCs.  
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 To further investigate whether neointimal SMCs may arise from c-Kit+ cells within a donor graft, 
tdTomato-labeled aortic segments from Kit-CreER;Rosa26-tdTomato mice were transplanted into BALB/c 
mice, and grafts were collected for analysis four weeks later (Online Figure XA). Successful labeling of 
tdTomato in the aorta before transplantation was confirmed by whole mount fluorescence microscopy 
(Online Figure XB, left panel). Interestingly, although we observed neointimal SMC accumulation in aortic 
grafts, no tdTomato+ cells were detected by both whole mount fluorescence view and immunostaining 
sections (Online Figure XB-C). Collectively, these results demonstrate that c-Kit+ cells from recipient, but 
not donor mice, are essential contributors to neointimal SMC accumulation in an allograft model. 
 
Non-bone marrow source of c-Kit+ cells differentiate into neointimal SMCs, while bone marrow c-Kit+ cells 
give rise to CD45+ leucocytes in transplant arteriosclerosis. 
 
We next sought to address whether recipient c-Kit+ cells originate from bone marrow or non-bone 
marrow tissues. Chimeric mice were generated, in which bone marrow cells from Kit-CreER;Rosa26-
tdTomato mice were transferred to irradiated wildtype C57BL/6J mice, and further pulsed with tamoxifen 
and subjected to allograft transplantation (Figure 3A). Successful reconstitution of bone marrow from 
tdTomato mice was confirmed by the detection of tdTomato+ cells in bone marrow, peripheral blood, as 
well as aortic graft (Online Figure XI; Figure 3B). Although tdTomato+ cells were detected in neointimal 
lesions, only ~1% neointimal SM22+ cells were tdTomato+ (Figure 3B and 3D), suggesting the origin of 
most c-Kit-derived SMCs was non-bone marrow tissues.  
 
 Although most bone marrow c-Kit-derived cells do not produce SMCs, this population may also play 
an important role in allograft-induced neointima formation. Considering that transplant arteriosclerosis is 
mediated by alloimmune reactions, we supposed that this bone marrow c-Kit-derived population could be 
CD45+ leucocytes. CD45 staining was further performed in both chimeric model and the allograft model 
from Figure 2. Our results showed that around half of tdTomato+ cells were positive for CD45 in the 
allograft model from Figure 2 (Online Figure IXA-B), while most (~95%) tdTomato+ cells expressed CD45 
in this chimeric model (Figure 3C-3D). Of note, tdTomato-CD45+ cells were also observed in allograft from 
the chimeric model (Figure 3C), suggesting that not all CD45+ cells are derived from bone marrow c-Kit 
lineage cells. Our data further showed that most tdTomato+CD45+ cells and tdTomato+SM22+ cells were 
separate populations (Online Figure IXC). Thus, bone marrow-derived c-Kit+ cells mainly generate CD45+ 
leucocytes, rather than SMCs, and may also be an important contributor to neointima formation. 
 
Blocking of c-Kit by ACK2 significantly ameliorates allograft-induced neointima formation. 
 
Data so far suggested that recipient non-bone marrow c-Kit+ cells produce SMCs, while bone marrow c-
Kit+ cells generates leucocytes. We next asked whether blocking of c-Kit could abrogate neointima 
formation in our model. ACK2, a monoclonal antibody reacting against the extracellular domain of c-Kit, 
has been reported to specifically target c-Kit+ cells and block c-Kit function27, and was further used in our 
experiments. Kit-CreER; Rosa26-tdTomato mice pulsed with tamoxifen were subjected to allograft 
transplantation (Figure 4A). Immediately after transplantation, ACK2 or control IgG mixed with Pluronic 
F-127 Gel was applied to the adventitial side of the grafts, which allows a slow release of ACK2 to the local 
graft microenvironment28. Four weeks later, graft tissues were harvested for analyses (Figure 4A). Whole 
mount fluorescence analyses showed a significant decrease of tdTomato in ACK2 group compared to IgG 
group (Online Figure XII), indicating that ACK2 markedly reduced accumulation of c-Kit-derived cells in 
the graft. ACK2 reduced neointima formation in both zone 3 (~53%) and zone 4 (~64%), as well as 
accumulation of neointimal tdTomato+ cells (decreased by ~25% in zone 3, and ~68% in zone 4) and SM22+ 
cells (decreased by ~16% in zone 3, and ~64% in zone 4) (Figure 4B-4D). More importantly, the number 
of neointimal tdTomato+ SM22+ cells was also downregulated in ACK2 group, by ~45% in zone 3 and ~78% 
in zone 4 (Figure 4B and 4D). Staining of α-SMA and calponin was also performed and showed similar 
results (Online Figure XIII). The percentage of tdTomato+ SM22+ cells in total SM22+ cells was lower in 
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ACK2 group in both zones (Figure 4E, left panel). While the percentage of tdTomato+ SM22+ cells in total 
tdTomato+ cells was reduced by 28% (although not significant, P=0.07) in zone 3, it was significantly 
decreased by ~22% in zone 4 (Figure 4E, right panel). Notably, variable co-staining of SM22 and tdTomato 
was also observed in different sections (Figure 4B-4E, Online Figure XIV). Although we cannot exclude 
the possibility that ACK2 may also impair neointima formation via other unknown effects, these data 
provide clear evidence to support the critical role of c-Kit+ cells in neointimal formation of allograft mouse 
model. 
 
SCF induces c-Kit+ cell migration. 
 
Previous reports have shown that SCF, a specific ligand for c-Kit, can mediate cell survival and 
proliferation as well as SMC migration17. To examine the possible mechanisms underlying c-Kit+ cell 
migration to the lesions and subsequent differentiation into neointimal SMC, SCF presence was measured 
in blood and the vessel wall of allograft models. A significant increase in SCF concentrations in peripheral 
blood was observed after allograft transplantation (Online Figure XVA). Compared to control aorta, 
significant increases of both SCF and tdTomato were detected and found to be co-localized in the allograft 
(Figure 5A), suggesting a possibility that increased accumulation of SCF may induce migration of c-Kit+ 
cells to the lesion sites. Control aorta from donor BALB/c mice, and donor aortic grafts one day after 
allograft transplantation were also analyzed and showed that SCF was markedly increased in the adventitia 
of aortic graft only one day after transplantation (Online Figure XVI). More importantly, accumulation of 
recipient tdTomato+ cells were detected in the adventitia where SCF was highly expressed (Online Figure 
XVI), further supporting that SCF may induce c-Kit+ cell migration. 
 
 To further validate our hypothesis, we isolated c-Kit+ cells from these grafts from wildtype mice as 
previously described12. Phenotypic analyses by flow cytometry showed that most isolated c-Kit+ cells 
expressed classical stem/progenitor markers including Sca-1 and CD34, fibroblast or mesenchymal stem 
cell marker CD140a (PDGFRα), but not leucocyte marker CD45 or SMC marker α-SMA (Online Figure 
XVII). Moreover, these isolated c-Kit+ cells can be cultured for over 30 passages without significant 
changes in vitro (data not shown), suggesting that these isolated c-Kit+ cells displayed stem/progenitor 
properties and may represent a population of SPC and/or fibroblast in vivo. We next determined whether 
SCF could induce migration of these isolated c-Kit+ cells in vitro. Both transwell migration assay and 
scratch wound healing assay showed that SCF significantly increased migration of c-Kit+ cells in a dose-
dependent manner (Figure 5B, Online Figure XVIIIA). As blocking of c-Kit by ACK2 could markedly 
reduce neointima formation in vivo, we determined if ACK2 could also reduce SCF-induced c-Kit+ cell 
migration in vitro. As expected, ACK2-treated cells showed a significantly lower migration rate than a 
control IgG group in response to SCF stimulation (Figure 5C), without affecting cell proliferation in c-Kit+ 
cells (Online Figure XVIIIB-C). Taken together, our data provide evidence that SCF is a chemotactic factor 
that induces c-Kit+ cell migration in vitro.  
 
Activation of SCF/c-Kit signaling pathway regulates c-Kit+ cell migration. 
 
We next investigated the underlying mechanisms behind SCF-mediated cell migration. Considering 
that reorganization of the actin cytoskeleton is critical in triggering cell migration29, we first performed 
immunostaining to observe the actin cytoskeleton and focal adhesions in c-Kit+ cells, using fluorescent-
phalloidin, which specifically binds actin, and antibodies against phosphorylated focal adhesion kinase (p-
FAK) and vinculin to stain focal adhesion assembly. SCF immediately induced formation of parallel 
elongated-stress fibers and cell spreading in c-Kit+ cells, compared to untreated cells (Figure 5D). Filopodia 
and lamellipodia were formed at the leading edge of c-Kit+ cells within 2 min of SCF treatment. Moreover, 
co-staining of p-FAK, vinculin and F-actin was also observed at the leading edge (Figure 5D), which is an 
indicative of cell migration. These data suggest that SCF may trigger cell migration at a very early time 
point. As SCF has been reported to specifically bind and activate c-Kit, we sought to investigate whether 
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c-Kit signaling pathways regulates this early process. Phosphorylation of c-Kit was increased by SCF within 
minutes (Figure 5E, upper panel), indicating that early activation of c-Kit signaling may regulate this 
process. Small GTPases, which can be activated by tyrosine kinase, have been shown to be pivotal in 
regulating cytoskeleton reorganization and cell migration29. As c-Kit is a receptor tyrosine kinase, we 
performed a G-LISA activation assay to test the activation of GTPases. We showed that SCF treatment led 
to early activation of small GTPases including cell division cycle 42 (Cdc42), Ras homolog family member 
A (RhoA) and Rac family small GTPase 1 (Rac1) within 2 min (Figure 5F). Possible downstream pathways 
of c-Kit signaling and/or GTPases including phosphorylation of MEK1/2, ERK1/2 and myosin light chain 
(MLC) were also elevated shortly after SCF stimulation (Figure 5E, lower panel). Activation of MLC may 
further promote cell contractility and cell motility30. Phosphorylation of JNK and c-Jun was also increased 
at a later time point of 30 min (Figure 5G). Because both MEK/ERK and JNK/c-Jun have been reported to 
regulate expression of matrix metalloproteinases (MMPs) to degrade extracellular matrix and ease cell 
migration31, we further measured secretion of MMPs in cell culture supernatants. A significant increase in 
MMP-2, but not MMP-9, was detected after SCF treatment for 24 h and 48 h (Figure 5H, Online Figure 
XVIIID), suggesting a possible role of MMP-2 in regulating cell migration at a later time. Notably, ACK2 
could completely or at least partially block the activation of c-Kit signaling, as well as migration-related 
pathways including the MEK/ERK/MLC, JNK/c-Jun pathways (Figure 5I). siRNA-mediated knockdown 
of Kit effectively reversed SCF-induced cell migration (Figure 5J-5K). These results collectively indicate 
that SCF/c-Kit signaling, upstream of MEK/ERK and JNK pathways, is critical for cell migration in c-Kit+ 
cells. tdTomato-labeled c-Kit+ cells were also isolated from the grafts of Kit-CreER;Rosa26-tdTomato 
mouse using the same method. Flow cytometric analysis confirmed most isolated c-Kit+ cells were 
tdTomato positive (Online Figure XIX). Consistent with our results obtained from non-labeled c-Kit+ cells, 
SCF also increased migration of tdTomato-labeled c-Kit+ cells in vitro (Figure 5L). 
 
TGFβ1 induces c-Kit+ cell differentiation into SMCs.  
 
Our data so far suggested that SCF triggers c-Kit+ cell migration in vitro, we next investigated whether 
SCF could also induce c-Kit+ cell differentiation into SMC, as most isolated c-Kit+ cells do not express SMC 
marker α-SMA (Online Figure XVII). Our results showed that SCF did not affect expression of SMC 
markers (Online Figure XXA-B). TGFβ1 has been reported to increase in human primary atherosclerotic 
and restenotic arteries32, as well as various mouse vascular disease models8, 33, 34. We found that TGFβ1 was 
also significantly increased in the blood plasma of allograft mice (Online Figure XVB). Moreover, 
immunostaining showed increased expression of TGFβ1 in the allograft compared to aorta from control 
mice (Figure 6A), indicating a possible functional role of TGFβ1. To test this hypothesis, we treated c-Kit+ 
cells with TGFβ1 and measured SMC markers in vitro. Both gene and protein expression of SMC markers 
were markedly increased in c-Kit+ cells exposed to TGFβ1 (Figure 6B-6D), which was also confirmed by 
immunostaining (Figure 5F). While TGFβ1 upregulated SMC markers in these cells, stem/progenitor 
markers including Kit, lymphocyte antigen 6 complex, locus A (Ly6a) and Cd34 were significantly 
decreased (Figure 6E), suggesting that c-Kit+ cells would downregulate stem/progenitor markers once 
differentiated. Cell migration was also tested and we showed that c-Kit+ cell migration was not affected by 
low doses of TGFβ1 but was downregulated by higher doses of TGFβ1 (Online Figure XXC). Besides, 
tdTomato-labeled c-Kit+ cells treated with TGFβ1 also showed similar SMC differentiation capacity, as 
shown by the increased expression of SMC markers in immunostaining images (Figure 6G). Taken together, 
these data suggest that TGFβ1 can induce c-Kit+ cell differentiation into SMC in vitro. 
 
Glucose metabolism is critical for TGFβ1-induced c-Kit+ cell differentiation into SMC. 
 
We further investigated the mechanisms underlying TGFβ1-induced c-Kit+ cell differentiation into 
SMC. Accumulating evidence has demonstrated that cellular metabolism plays a vital role in regulating cell 
proliferation, differentiation and function in various cell types35-37. A recent report revealed that satellite 
cells, the adult resident skeletal muscle stem cells, switched cellular metabolism to glycolysis to activate 
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muscle gene expression and cell differentiation38, suggesting that cellular metabolism may regulate resident 
stem cell differentiation. We first examined glucose metabolism during TGFβ1-induced c-Kit+ cell 
differentiation. 2-NBDG assay showed that glucose uptake was significantly increased in c-Kit+ cells in a 
time-dependent manner (Figure 6H). Real-time monitoring of extracellular acidification rate (ECAR) and 
mitochondrial oxygen consumption rate (OCR) was then performed. ECAR is a measure of glycolysis-
driven lactate production, while OCR indicates mitochondrial oxidative metabolism. Our results showed 
that TGFβ1 rapidly increased ECAR and this high ECAR level was maintained during 7-hour metabolic 
monitoring, while OCR remained unchanged (Figure 6I). We then measured metabolism in cells treated 
with TGFβ1 for one and three days. c-Kit+ cells showed high ECAR level after one day (Figure 6J, Online 
Figure XXIA) and displayed even higher levels in ECAR three days later (Figure 6K, Online Figure XXIB), 
indicating that TGFβ1 dramatically increases glycolysis in c-Kit+ cells. No changes were seen in basal OCR 
after one or three days. However, we did observe an increasing trend in both spare respiratory capacity 
(SRC) and maximal OCR after 1 day, and a significant increase after 3 days (Figure 6J-6K, Online Figure 
XXIA-B), suggesting an increased ability to utilize mitochondrial oxidative metabolism in these cells. 
Consistent with changes in OCR, mitochondrial mass was also observed to be slightly increased after 1 day, 
and markedly upregulated after 3 days TGFβ1 treatment (Online Figure XXIC).  
 
 We next determined whether increased glucose metabolism and glycolysis are essential for cell 
differentiation. Hexokinase (HK), which converts glucose into glucose-6-phosphate, is a rate-limiting 
enzyme in glucose metabolism and may play a role in this process. Gene expression of different HK 
isozymes was tested and results showed that c-Kit+ cells mainly expressed Hk1 and Hk2 (Figure 7A). 
Western blot analysis showed that while untreated c-Kit+ cells expressed HK1 and HK2 protein (0 time 
point), TGFβ1 significantly increased both HK1 and HK2 in a time-dependent manner (Figure 7B). 
Moreover, HK activity was also upregulated (Figure 7C), implicating activation of HK glycolytic activity. 
We then used 2-deoxyglucose (2DG), a glucose analog which can be phosphorylated by HK to form 2-
deoxyglucose-6-phosphate and cannot be further metabolized39, to block glucose metabolism and examine 
cell differentiation. 2DG effectively reduced TGFβ1-induced SMC markers (Figure 7D). Meanwhile, 
glycolysis, as shown by basal and max ECAR, was also downregulated in cells treated with both 2DG and 
TGFβ1 (Figure 7E). Interestingly, 2DG also reduced both SRC and max OCR (Figure 7F), indicating that 
glucose metabolism may contribute to the increased ability to use mitochondrial metabolism in these cells. 
Furthermore, siRNA-mediated knockdown of Hk1, but not Hk2, effectively reduced SMC markers 
increased by TGFβ1 (Figure 7G, Online Figure XXIII). Glycogenolysis could also be a cell-intrinsic source 
of glucose and contribute to glycolysis40. We examined the expression of different isozymes of glycogen 
phosphorylase (PYG), a rate-limiting enzyme regulating glycogen breakdown pathway, and showed that 
Pygb is expressed in c-Kit+ cells (Online Figure XXIVA). However, blocking of PYG by a selective 
inhibitor CP-91149 did not affect TGFβ1-increased SMC markers (Online Figure XXIVB). Taken together, 
our data unravel an essential role of HK1-dependent glucose metabolism in regulating TGFβ1-induced c-
Kit+ cell differentiation into SMC in vitro. To test whether HK1 may be also involved in c-Kit-derived 
neointimal SMC formation in vivo, HK1 staining was performed in both normal aorta and allograft sections. 
In normal aorta, HK1 was detected in both medial SMCs and adventitial tdTomato+ cells, with a higher 
expression in SMCs than tdTomato+ cells (Figure 7H, upper panel). In the allograft, a population of 
tdTomato+SM22+ cells with high HK1 expression was detected in the neointima, whereas some SM22-
tdTomato+ cells with low HK1 expression was also observed (Figure 7H, lower panel). Thus, these 
immunostaining data might suggest a possible role of HK1 in regulating SMC differentiation from c-Kit+ 
cell in vivo. 
 
 Growing evidence has suggested an essential role of cellular metabolism in the regulation of 
epigenetics including acetylation, methylation and glycosylation41. The hexosamine biosynthetic pathway, 
a branch of glucose metabolism, produces uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) as a 
substrate for protein O-GlcNAcylation, which may further modulate protein function42. We then tested 
whether O-GlcNAcylation was involved in TGFβ1-induced cell differentiation. Our results showed that 
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total protein O-GlcNAcylation was upregulated in TGFβ1-treated c-Kit+ cells (Figure 8A). Moreover, both 
gene and protein analyses revealed that SMC markers increased by TGFβ1 were markedly reversed by 6-
Diazo-5-oxo-L-norleucine (DON), an inhibitor of O-GlcNAcylation (Figure 8B, C), suggesting a possible 
role of protein O-GlcNAcylation in regulating cell differentiation. Myocardin and serum response factor 
(SRF) are important transcription factors for regulating smooth muscle gene expression43. We showed that 
TGFβ1 increased expression of total myocardin, and nuclear translocation of both myocardin and SRF in 
c-Kit+ cells (Figure 8D-8E). Interestingly, both myocardin and SRF could be modified by O-GlcNAcylation, 
as O-GlcNAcylation of both proteins was significantly increased by TGFβ1 (Figure 8F). Accumulation of 
O-GlcNAcylation of myocardin was also found in both the cytoplasm and the nucleus in TGFβ1-treated c-
Kit+ cells (Figure 8G). Collectively, these data suggest a possible role of O-GlcNAcylation, which is derived 
from glucose metabolism, in regulating SMC differentiation, and that O-GlcNAcylation of myocardin and 
SRF may also participate in this process. O-GlcNAcylation of myocardin was further tested in both normal 
aorta and allograft sections. In normal aorta, co-staining of myocardin and O-GlcNAc was observed in 
some medial SMCs underlying the intimal layer, but not in adventitial tdTomato+ cells, indicating that O-
GlcNAcylation of myocardin may exist in a population of SMCs under physiological conditions (Figure 
8H, upper panel). While tdTomato+ myocardin+ SMCs were detected in the allograft lesions, these cells 
were found to co-express O-GlcNAc, suggesting that O-GlcNAcylation of myocardin may be involved in 
SMC differentiation from c-Kit+ cells in vivo.   
 
 
DISCUSSION 
 
Arteriosclerosis is characterized by EC dysfunction and thickening of the neointima in which SMCs 
accumulate5. However, the origin of these neointimal SMCs is still under intense scrutiny4. Recent studies 
have suggested an important role for resident SPCs in vascular remodeling12-14, 16. Multiple SPCs including 
c-Kit+ SPCs have been identified in both mouse and human aortic adventitia and atherosclerotic lesions12, 
44, 45. Previous studies have established that c-Kit is primarily expressed in hematopoietic cells, germ cells, 
melanocytes, interstitial cells of Cajal, mast cells as well as tissue-resident stem/progenitor cells17. In this 
study, we first showed the heterogeneity of adventitial c-Kit+ cells in the blood vessels. While a large 
population expresses classical SPC markers Sca-1 and CD34, other populations including c-Kit+ CD45+ 
cells (adventitial macrophage progenitor cell or leucocyte) and c-Kit+ PDGFRα+ cells (fibroblast or 
mesenchymal stem cell) were also identified. These data suggest that c-Kit is expressed in multiple cell 
types. Importantly, c-Kit+ cells expressing classical stem/progenitor cell markers Sca-1 and CD34 were also 
observed within the neointima of aortic grafts, indicating a possible role of c-Kit+ SPCs in allograft-induced 
arteriosclerosis. Using an inducible genetic lineage tracing model, we provided the first evidence that c-
Kit+ cells are critical contributors of neointimal SMCs in allograft transplantation. Our data that a significant 
higher proportion of c-Kit-derived SMCs in both sides of the aortic grafts than in the middle part, suggest 
c-Kit lineage cells within the adjacent carotid artery could possibly be an important source of these c-Kit-
derived SMCs. Our in vitro data showed that c-Kit+ cells isolated from the grafts displayed stem/progenitor 
cell properties and differentiate into SMCs, further supporting a possible role of c-Kit+ SPCs. Thus, c-Kit+ 
SPCs may contribute to neointima formation in our allograft model. However, as c-Kit labels multiple cell 
types in the vessel wall in our lineage tracing model, the exact identity of c-Kit lineage cells contributing 
to SMCs still remains unclear. 
 
 Based on lineage tracing mouse models, several groups have provided substantial evidence that pre-
existing SMCs contribute to neointima formation in vascular diseases46-52. Recently, Roostalu et al.16 
revealed that CD146+ SMC progenitors contribute to neointimal formation in a mild wire-injury model, but 
not in a severe transluminal injury model, in which they further suggested adventitial SPCs may play a role. 
Yuan et al.53 showed that neointima could be heterogeneous and showed different phenotypes even in the 
same vascular injury model. While pre-existing MYH11+ SMCs give rise to most of the neointimal SMCs 
in one type of neointima, Sox10+ SPCs alongside with MYH11+ SMCs contribute to form another type53. 
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Thus, the relative contribution of different cell types to neointima formation could be highly context 
dependent. Chen et al54 recently showed that c-Kit+ cells rarely contributed to SMCs of neointimal lesions 
in wire-injured and carotid artery-ligation models. In our present study, we used a transplant arteriosclerosis 
mouse model, which is a severe vascular injury model mediated by alloimmune response, leading to the 
loss of most, if not all, mature SMCs within the vessel wall. We demonstrated that ~5 to 55% (depending 
on the regions analyzed) of neointimal SMCs in the allograft are derived from c-Kit+ cells. These seemingly 
contradicting results, however, could be due to the vascular disease models employed, the extent and 
severity of vascular injury, i.e. completely loss of mature SMCs or not, as well as the vascular regions 
analyzed. Thus, the relative contribution of certain cell types to neointima formation could be highly 
dependent on the severity of the vessel injury. Besides, we also observed a minor population of c-Kit+ 
medial SMCs. We cannot exclude that this minor population, if any, may also contribute to neointimal 
SMCs in our model, as recent studies have indicated that clonal expansion of a few medial SMCs contribute 
to atherosclerosis48-50, 52. Also, we observed a much higher labeling of medial SMCs by tdTomato in the 
region adjacent to the graft (zone 2) compared to distant region (zone 1). The expanded c-Kit-derived SMCs 
in this region may be derived from adventitial tdTomato+ cells like SPCs, or even pre-existing medial 
tdTomato+ SMCs, both of which could be possible contributors to neointimal tdTomato+ SMCs. 
 
 The origin of c-Kit-derived SMCs was further proved to be recipient mice, but not donor grafts. One 
possible explanation is that cells from donor grafts including ECs, SMCs and even SPCs may undergo 
apoptosis due to severe alloimmune response23-26. During this process, inflamed or apoptotic vascular cells 
might release cytokines to recruit recipient c-Kit+ cells to the injury sites, which is supported by our results 
that increased levels of cytokines such as SCF and TGFβ1 were detected in both grafts and peripheral blood. 
Bone marrow is an important source of SPCs, however, it remains controversial whether newly-formed 
neointimal SMCs arise from bone marrow-derived SPCs9, 23, 55-58. Our data revealed that c-Kit-derived 
SMCs are not from bone marrow, as bone marrow-derived c-Kit+ cells rarely co-stained with SMC markers 
in neointima, supporting the conclusion that neointimal SMCs are derived from non-bone marrow tissues23, 
56-58. Although c-Kit-derived SMCs do not arise from bone marrow, we did observe bone marrow-derived 
c-Kit+ cells in neointima, which was further suggested to be CD45+ leucocytes that may mediate alloimmune 
responses and drive neointima formation. Despite the fact that most bone marrow-derived c-Kit+ cells give 
rise CD45+ leucocytes in our chimeric mouse model, a number of tdTomato-CD45+ cells were also detected 
(Figure 3C). We speculate that other c-Kit- cells, or even c-Kit+ cells from non-bone marrow tissues like the 
vessel wall, adjacent lymph nodes or spleen, may also contribute to the total CD45+ cells in the graft. 
Although our in vivo data highlight the importance of recipient c-Kit-derived SMCs, the exact origin of 
these cells remains unclear. Our results that a significant higher proportion of c-Kit-derived neointimal 
SMCs in graft regions proximal to carotid artery than distal regions (Figure 2), suggest c-Kit+ cells may 
probably migrate from adjacent carotid artery to the graft. Supporting this notion is the finding by Hagensen 
et al.59 that flanking recipient vasculature contributes to smooth muscle accumulation in murine allograft 
vasculopathy. Alternatively, these c-Kit-derived SMCs may also be derived from perivascular tissues, 
including adventitia and perivascular adipose tissues, which also contain an abundant population of stem 
cells (data not shown). The transplanted vessels are embedded with recipient perivascular tissues that may 
directly migrate into intima where they differentiate into SMCs. Other possible sources include adipose 
tissue, spleen and liver that have been reported to harbor SPCs60-62, among which we have also identified 
tdTomato labeled c-Kit+ cells in the spleen and liver. Further investigation will be needed to confirm the 
exact origin and identity of these c-Kit-derived SMCs.  
 
 We showed that the proportion of c-Kit-derived neointimal SMCs varies in different regions, 
suggesting that neointima formed in different regions may be heterogeneous and consist of neointimal 
SMCs from different lineages. A significant higher proportion of c-Kit-derived SMCs was observed in a 
more severe and irregular neointimal region (zone 3), indicating a possibility that c-Kit-derived SMCs may 
be related to more disorganized and severe neointima. We also observed a population of adventitial c-Kit-
derived SMCs, which showed a more consistent features across different zones and could be a distinct 
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
 DOI: 10.1161/CIRCRESAHA.119.314855   12 
population from neointimal c-Kit-derived SMCs. Thus, it would very be interesting to further investigate 
the heterogeneity and clonality of c-Kit+ cells, such as using a multicolor lineage tracing model. 
 
 The mechanisms underlying c-Kit+ cell homing to lesion sites and further differentiation into SMCs 
were also investigated in our study. Our data showed a significant increase of SCF with infiltration of c-
Kit+ cells in the lesion sites four weeks after transplantation. Moreover, migrating c-Kit+ cells were readily 
observed in SCF-abundant adventitia only one day after transplantation, suggesting that SCF may serve as 
a chemotactic factor for c-Kit+ cells in our allograft model. Our in vitro studies further demonstrated that 
SCF induces c-Kit+ cell migration through SCF/c-Kit signaling. Amelioration of neointima formation in 
vivo as well as c-Kit+ cell migration in vitro by ACK2 treatment highlights the importance of SCF/c-Kit 
signaling in this process, consistent with some previous studies using wire-injury models63, 64. SCF has 
previously suggested to be mainly expressed by endothelial cells and fibroblasts throughout the body17. Our 
data showed that SCF is expressed in intimal ECs, a small population of SMCs and adventitial c-Kit+ cells 
under normal and diseases conditions (Online Figure XVI, Figure 5A). Thus, we speculate that recipient c-
Kit+ cells might be guided by SCF, which may be secreted by inflamed or injured above-mentioned cells 
from donor graft in response to alloimmunity, and recruited to lesion sites to promote neointima formation. 
Our in vitro data showed the SCF/c-Kit axis also triggers a possible downstream activation of small 
GTPases, MEK1/2-ERK1/2-MLC and JNK/c-Jun signaling pathways to regulate cytoskeleton 
rearrangement, myosin contractibility and MMP-2 secretion, which eventually leads to cell migration 
(Online Figure XXV).  
 
 Despite the effect of SCF on cell migration, SCF does not induce c-Kit+ cell differentiation into SMC 
in vitro. TGFβ1 has been reported to be significantly increased in vascular diseases8, 32-34. In our allograft 
mouse model, similar results were obtained as seen by the accumulation of TGFβ1 in local neointimal 
lesions and peripheral blood. Our data further demonstrate that TGFβ1 could promote c-Kit+ cell 
differentiation into SMCs, but not cell migration in vitro. Glucose metabolism was reported to be elevated 
in atherosclerotic lesions as well as neointimal lesions65-67. Moreover, alteration in cellular metabolism has 
been reported to regulate cell proliferation, differentiation and function35-37. We observed significant 
increases in glucose metabolism and glycolysis during TGFβ1-induced c-Kit+ cell differentiation into SMC. 
Importantly, both glucose metabolism and SMC differentiation could be effectively abrogated by 2DG or 
HK1 knockdown, suggesting a critical role of HK1-dependent glucose metabolism in TGFβ1-induced cell 
differentiation (Online Figure XXVB).  
 
 Increasing glucose metabolism in c-Kit+ cell may provide biosynthetic substrates as well as energy for 
cell growth and differentiation. Moreover, cellular metabolism can also provide substrates for post-
translational modifications of proteins such as acetylation, methylation and glycosylation41. The 
hexosamine biosynthetic pathway is a branch from glucose metabolism that produces UDP-GlcNAc as a 
substrate for protein O-GlcNAcylation42. We showed that O-GlcNAcylation of total proteins was increased 
in TGFβ1-treated cells and that blocking O-GlcNAcylation by DON reversed TGFβ1-induced cell 
differentiation, indicating a possible role of O-GlcNAcylation in regulating SMC differentiation. 
Interestingly, we further identified that SRF and myocardin, both of which are important regulators in SMC 
differentiation, could be modified by O-GlcNAcylation. O-GlcNAcylation of myocardin was further proved 
to be increased both in the cytoplasm and nucleus. Previous reports have indicated possible modification 
of SRF by O-GlcNAcylation68, but how this modification may affect SRF remains unknown. It has also 
been reported that both O-GlcNAcylation and phosphorylation can modify serine or threonine residues of 
proteins, and that they may sometimes exert opposite roles in modulating intracellular signaling and gene 
transcription69. While phosphorylation of SRF may either promote or inhibit its transcriptional activity, 
phosphorylation of myocardin was shown to decrease SMC gene expression70. Therefore, we propose that 
a balance between O-GlcNAcylation and phosphorylation of SRF and myocardin may alter their 
transcriptional activity to regulate SMC gene expression (Online Figure XXVB). Further investigations are 
still needed to prove the functional role of O-GlcNAcylation of SRF and myocardin in SMC differentiation. 
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Interestingly, increased HK1 and O-GlcNAcylation of myocardin were also detected in a population of c-
Kit-derived neointimal SMCs compared to adventitial c-Kit+ cells, suggesting that these in vitro 
mechanisms might happen in vivo. Our data here provide a possible mechanism for c-Kit+ cell migration 
and differentiation, however, we cannot exclude that other mechanisms, or multiple mechanisms 
synergistically, contribute to this process. Also, it should be noted that the metabolic effects of TGFβ1 is 
not only restricted to c-Kit+ cells, as metabolic reprogramming driven by TGFβ1 has also been detected or 
suggested in other cells involved in vascular remodeling71-74 (Online Figure XXII).  
 
 Although our current study demonstrates the critical role of c-Kit+ cells in transplant arteriosclerosis, 
our finding that vascular resident c-Kit+ cell is a heterogeneous population makes it difficult to interpret 
which non-bone marrow c-Kit population generates smooth muscle cells in our current study. This is a 
technical limitation of the lineage trancing mouse model we used, as c-Kit did not specifically label vascular 
stem/progenitor cells as expected. To demonstrate the role of vascular stem/progenitor cells in the 
generation of neointimal smooth muscle cells, further genetic lineage tracing with dual recombinase 
system75 could be used to solve this problem. 
 
 In summary, we have demonstrated here that recipient non-borrow sources of c-Kit+ cells give rise to 
SMCs and contribute to neointima formation in an allograft transplantation model. Activation of the SCF/c-
Kit axis promotes c-Kit+ cell migration, while TGFβ1-driven glucose metabolism induces cell 
differentiation into SMCs in vitro. These findings may provide novel insights into the pathogenesis of 
neointima formation and have further potential therapeutic implications for vascular diseases. 
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FIGURE LEGENDS 
 
Figure 1. Characterization of c-Kit+ cells in mouse aorta. A, Representative images of normal aorta from 
wildtype C57BL/6J mice, stained for c-Kit, Sca-1, CD34, PDGFR-α and CD45 (n=6 per group). Arrows 
indicate examples of double positive cells. B, Strategy for Kit-CreER; Rosa26-tdTomato mice generation 
and experimental schedule of tamoxifen-induced tdTomato labelling of c-Kit+ cells. C, Representative flow 
cytometric analysis of tdTomato+ cells in bone marrow and aorta (n=6 per group). D, Representative images 
showing staining of tdTomato, c-Kit, Sca-1, CD34, PDGFR-α and CD45 in the control (corn oil) or 
tamoxifen-treated mice (n=6 per group). Arrows indicate examples of co-staining cells. E, Quantification 
of co-staining cells of WT aorta in A and tdTomato-labeled aorta in D. Data represent mean ± SEM, n=3. 
Scale bars, 50 μM (white) and 10 μM (yellow). A indicates adventitia; M, media; I, intima; CTR, control; 
TAM, tamoxifen; tdT, tdTomato.  
 
Figure 2. Recipient c-Kit+ cells repopulate SMCs in transplant arteriosclerosis. A, Schematic showing 
procedure for allograft transplantation experiments. After Kit-CreER; Rosa26-tdTomato mice received 
tamoxifen injection, aortic segments from BALB/c mice were transplanted into these mice and grafts were 
collected 4 weeks after surgery (n=6 per group). B, Representative whole mount images showing tdTomato 
labelling in aortic grafts with adjacent tissues (n=3). Scale bars: 5 mm. C, Schematic showing distinct zones 
of aortic graft with adjacent carotid arteries. Zone 1 is carotid artery that lies distal from the site of 
anastomosis. Zone 2 is carotid artery proximal to the site of anastomosis and encompasses the suture site. 
Zone 3 and Zone 4 are aortic grafts proximal to, or distal from the site of anastomosis, respectively. D, 
Representative images showing different zones of aortic allograft with adjacent carotid arteries, stained 
with tdTomato and SM22. Arrows indicate tdTomato+SM22+ cells. Scale bars, 50 μm (white) and 10 μm 
(yellow). E, Graphs showing quantification of tdTomato expression in SM22+ SMCs or SM22 expression 
in tdTomato+ cells. Data represent mean ± SEM, n=6 in Zone 2, n=12 in Zone 3 and 4. A indicates adventitia; 
M, media; I, intima or neointima; CA, carotid artery; R1-2, region 1-2; tdT, tdTomato. 
 
Figure 3. Non-bone marrow source of c-Kit+ cells repopulate neointimal SMCs, while bone marrow 
c-Kit+ cells give rise to CD45+ leucocytes in transplant arteriosclerosis. A, Strategy for generation of 
chimeric mouse model, in which bone marrow cells from Kit-CreER; Rosa26-tdTomato mice were 
transplanted into irradiated C57BL/6J mice, followed by tamoxifen treatment and allograft transplantation 
(n=6 mice per group). Aortic grafts were divided into different zones for analyses. B, Representative 
immunostaining images showing staining of tdTomato and SM22 in aortic grafts of chimeric mice. C, 
Representative immunostaining images showing staining of tdTomato and CD45 in aortic grafts of chimeric 
mice. Arrows indicate double positive cells. D, Quantification of tdTomato+, SM22+ and CD45+ cells in 
neointima or the whole graft. Data represent mean ± SEM, n=6 per group. Scale bars, 50 μm (white) and 
10 μm (yellow). A indicates adventitia; M, media; I, neointima; R1-2, region 1-2; tdT, tdTomato. 
 
Figure 4. Blocking of c-Kit+ cells by ACK2 ameliorates transplant arteriosclerosis. A, Schematic 
showing ACK2 or control IgG treatment in mouse allograft model (n=6 mice per group). Aortic grafts were 
divided into different zones for analyses. B, Representative images showing staining of tdTomato and SM22 
in Zone 3 and Zone 4 of the aortic graft from control IgG or ACK2 treated mice. Arrows indicate examples 
of co-staining cells. Scale bars, 50 μm (white) and 10 μm (yellow). C, Graphs showing quantification of 
neointimal and luminal areas. D, Graph showing quantification of relative cell number of tdTomato+ cells 
and SM22+ cells in the neointima. E, Graphs showing percentage of tdTomato+ cells in SMCs and SM22+ 
cells in total tdTomato+ cells in the neointima. Data represent mean ± SEM (n=5 in C, n=12 in D and E). 
*P<0.05, **P<0.01, ***P<0.001, by unpaired two-tailed t test (C-E). A indicates adventitia; M, media; I, 
neointima; tdT, tdTomato. 
 
Figure 5. SCF induces migration of c-Kit+ cells in vitro. A, Representative images showing tdTomato 
and SCF staining in control aorta from Kit-CreER; Rosa26-tdTomato mice described in Figure 1B, and 
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
 DOI: 10.1161/CIRCRESAHA.119.314855   19 
aortic allografts from mouse model described in Figure 2A (n=6 per group). Arrows indicate co-staining of 
tdTomato and SCF. B and C, Representative images showing SCF-induced c-Kit+ cell migration (B), with 
or without ACK2 or control IgG (C) by transwell migration assay. Graphs shown are relative cell number 
normalized to control. n=30 (10 random fields per experiment, 3 independent experiments) in B, n=15 (5 
random fields per experiment, 3 independent experiments) in C. D, Representative images showing cell 
morphology of SCF-treated c-Kit+ cells stained with p-FAK, F-actin and vinculin (n=3). E, Representative 
western blot showing activation of c-Kit, MEK-ERK-MLC pathways in response to SCF (n=3). F, Graphs 
showing activation of small GTPase including Cdc42, Rac1 and RhoA in SCF-treated c-Kit+ cells (n=3). G, 
Representative western blot indicating activation of JNK/c-Jun pathways in response to SCF (n=3). H, 
Quantification of MMP-2 in cell culture supernatant from SCF-treated c-Kit+ cells (n=3). I, Representative 
western blot showing signalling pathways in response to SCF for indicated times, in the presence of ACK2 
or IgG (n=3). J-K, c-Kit+ SPCs were transfected with negative control (NC) or Kit siRNA, and further 
treated with or without SCF. J, mRNA expression of Kit in different groups were measured to show the 
efficiency of siRNA knockdown (n=4). K, Transwell migration assay was used to determine cell mobility 
(n=5). L, tdTomato-labeled c-Kit+ cells were isolated from Kit-CreER; Rosa26-tdTomato mice to test cell 
migration in response to SCF. Images showed migrating cells on the transwell filter stained with tdTomato 
and DAPI (n=5). Scale bars, black (100 μm, in B, C and K), white (50 μm, in A and L) and 10 μm (yellow, 
in A and D). All data shown are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ###P<0.001, by unpaired 
two-tailed t test (L), one-way ANOVA with Dunnett’s test (B and F), one-way ANOVA with Tukey’s test 
(J and K), two-way ANOVA with Bonferroni’s test (C and H). A indicates adventitia; M, media; I, intima 
or neointima; R1-2, region 1-2. 
 
Figure 6. TGFβ1 induces c-Kit+ cell differentiation into SMC, accompanied by metabolic 
reprogramming. A, Representative images showing control aorta from Kit-CreER; Rosa26-tdTomato mice 
described in Figure 1B, and aortic allografts from mouse model described in Figure 2A stained with 
tdTomato and TGFβ1 (n=6 per group). B-F, c-Kit+ cells were treated with TGFβ1 (2 ng/ml) for 3 days to 
induce cell differentiation. B, qPCR analyses showing gene expression of smooth muscle markers in 
TGFβ1-treated c-Kit+ cells (n=10). C and D, Representative Western blot and quantification of smooth 
muscle markers (n=7). E, qPCR analyses of mRNA expression of stem/progenitor markers (n=7 or 10). F, 
Representative images showing staining of smooth muscle markers in c-Kit+ cells treated with TGFβ1 (n=3). 
G, tdTomato-labeled c-Kit+ cells were isolated from Kit-CreER; Rosa26-tdTomato mice to test cell 
differentiation in response to TGFβ1 for 3 days in vitro. Representative images showing staining of smooth 
muscle markers in tdTomato-labeled c-Kit+ cells treated with TGFβ1 (n=3). H, Representative histogram 
and quantification of 2-NBDG uptake in c-Kit+ cells treated with TGFβ1 for indicated times by flow 
cytometry (n=4). I, Real-time monitoring of ECAR and OCR in c-Kit+ cells treated with TGFβ1 within 7 
hours (n=4). J and K, c-Kit+ cells were treated with TGFβ1 for 1 day (J) or 3 days (K). Quantification of 
ECAR (n=4 in J, n=7 in K) and OCR (n=4 in J and K) are shown. All data shown are mean ± SEM. 
*P<0.05, **P<0.01, ***P<0.001, by unpaired two-tailed t test (B, D, E, J and K), or one-way ANOVA 
with Dunnett’s test (H). Scale bars, 50 μm (white) and 10 μm (yellow). A indicates adventitia; M, media; I, 
intima or neointima; Ctr, control; R1-2, region 1-2; tdT, tdTomato; Neg, negative control.  
 
Figure 7. Glucose metabolism is critical for TGFβ1-induced c-Kit+ cell differentiation into SMC. A, 
qPCR analyses for mRNA expression of four hexokinase isozymes in c-Kit+ cells (n=8 per group). B-C, c-
Kit+ cells were treated with TGFβ1 for indicated times. B, Representative western blot analyses of HK1 and 
HK2 in TGFβ1-treated c-Kit+ cells (n=3). C, Hexokinase activity in TGFβ1-treated cells for 24 h were 
analyzed (n=4 per group). D-F, c-Kit+ cells were treated with TGFβ1 and 2-DG (1 mM) for 48 h. 
Representative western blot analyses and quantification (D) of smooth muscle markers and quantification 
of ECAR (E) and OCR (F) were shown. n=4 per group in D, n=4-5 per group in E and F. G, qPCR analyses 
of mRNA expression of Hk1 and smooth muscle markers in c-Kit+ cells transfected with NC or HK1 siRNA, 
treated with or without TGFβ1 for 48 h (n=4 per group). H, Representative images showing staining of 
HK1, SM22 and tdTomato in normal aorta (from mouse model in Figure 1B) and allograft sections (from 
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mouse model in Figure 2A). Arrows indicate co-staining cells. Scale bars, 50 μm (white) and 10 μm 
(yellow). Data represent mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, #P<0.05, ##P<0.01, ###P<0.001, 
by unpaired two-tailed t test (C), and one-way ANOVA with Tukey’s test (D-G). Ctr indicates control; NC 
siRNA, negative control siRNA; A, adventitia; M, media; I, intima or neointima; R1-2, region 1-2. 
 
Figure 8. TGFβ1 induces O-GlcNAcylation of myocardin and SRF. A, Representative western blot 
showing protein O-GlcNAcylation in c-Kit+ cells after TGFβ1 treatment for 3 days (n=3). B and C, 
Quantification of mRNA expression (B) and representative western blot (C) showing expression of SMC 
markers in TGFβ1-treated c-Kit+ cells, with or without 5 μM DON treatment for 48 h. Data shown are mean 
± SEM. ***P<0.001, #P<0.05, ###P<0.001, by one-way ANOVA with Tukey’s test, n=7 per group. D and 
E, Representative western blot analysis of myocardin and SRF in total cell lysates (D), and cytoplasmic 
and nuclear lysates (E) of TGFβ1-treated c-Kit+ cells for indicated times (n=3). F, Representative western 
blot showing O-GlcNAcylation of myocardin and SRF in total cell lysates. Myocardin and SRF in TGFβ1-
treated c-Kit+ cells for indicated times or 3 days were immunoprecipitated and analyzed for protein O-
GlcNAcylation. Total myocardin and SRF are shown as input (n=3). G, Representative western blot 
showing O-GlcNAcylation of myocardin in cytoplasmic and nuclear lysates. Cytoplasmic and nuclear 
myocardin was immunoprecipitated and analyzed for protein O-GlcNAcylation, total myocardin are shown 
as input (n=3). H, Representative images showing staining of myocardin, O-GlcNAc and tdTomato in 
normal aorta (from mouse model in Figure 1B) and allograft sections (from mouse model in Figure 2A). 
Arrows indicate co-staining cells. Scale bars, 50 μm (white) and 10 μm (yellow). A indicates adventitia; M, 
media; I, intima or neointima; R1-2, region 1-2. 
 
 
  
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
 DOI: 10.1161/CIRCRESAHA.119.314855   21 
NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
 Neointimal lesions of allograft vessels mainly consist of smooth muscle cells. 
 
 c-Kit+ cells are present in bone marrow and most tissues/organs. 
 
 Whether c-Kit+ cells can differentiate into smooth muscle cells is unknown. 
 
What New Information Does This Article Contribute?  
 It is the first time to use genetic cell linear tracing to study smooth muscle cell origin in 
neointimal lesions of allografts. 
 
 c-Kit+ cells can differentiate into vascular smooth muscle cells. 
 
 
 These c-Kit+ stem/progenitor cell-derived smooth muscle cells are not bone marrow origin. 
 
 The mechanisms of stem/progenitor cell differentiation involves TGFβ1-driven glucose 
metabolism. 
The limitation of allograft organ survival is due to blocking the vessel lumen by neointimal lesions. We 
report a novel finding that stem/progenitor cells are a main source of smooth muscle cells in the lesion of 
allograft vessels. This result could help us to design a new drug to target the differentiation fate of 
resident stem cells to prevent lesion formation. 
 
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
FIGURE  1
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
FIGURE  2
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
FIGURE  3
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
FIGURE  4
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
FIGURE  5
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
FIGURE  6
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
FIGURE  7
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
FIGURE  8
D
ow
nloaded from
 http://ahajournals.org by on July 2, 2019
